Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality.

"Conflict of interest: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare no support from any additional organization for the submitted work. J.J.K. reports personal fees from Boehringer Ingelheim, outside the submitted work; O.H.K. reports grants from GSK, grants from Lygature, personal fees from Roche, outside the submitted work; F.B. reports personal fees from Boehringer Ingelheim, St Jude Medical, Boston Scientific, Medtronic, and Biotronic, outside the submitted work. All other authors declare no conflict of interest."

"Funding This work was supported by the Swedish Heart-Lung Foundation. The funding sources played no role in any part of the study. Ethics approvalThe study was approved by the Regional Ethical Review Board in Stockholm (EPN 2015/579-31/2).Conflict of interest: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare no support from any additional organization for the submitted work. J.J.K. reports personal fees from Boehringer Ingelheim, outside the submitted work; O.H.K. reports grants from GSK, grants from Lygature, personal fees from Roche, outside the submitted work; F.B. reports personal fees from Boehringer Ingelheim, St Jude Medical, Boston Scientific, Medtronic, and Biotronic, outside the submitted work. All other authors declare no conflict of interest."